amr

Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE study evaluating the Katana™ Thrombectomy System in acute pulmonary embolism patients. In parallel, Akura...

Position: Staff Software Engineer (Imaging) Location: Doha, Qatar Job Id: 663 # of Openings: 1 Company Overview Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its...

Position: Staff Software Engineer (Medical Imaging) Location: Doha, Qatar Job Id: 661 # of Openings: 1 Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE...

Position: Staff Software Engineer (Medical Imaging) Location: Doha, Qatar Job Id: 661 # of Openings: 1 Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE...

Position: Manager / Sr. Manager, Regulatory Affairs Location: Doha, Qatar Job Id: 666 # of Openings: 1 Akura Medical Overview Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE...

Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE study evaluating the Katana™ Thrombectomy System in acute pulmonary embolism patients. In parallel, Akura...

Position:Staff Software Engineer (Imaging) Location:Doha, Qatar Job Id:663 # of Openings:1 Company Overview Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE...

Position: Software Quality Test Engineer Location: Doha, Qatar Job Id: 660 # of Openings: 2 Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE study...

Position: Staff Software Engineer (Medical Imaging) Location: Doha, Qatar Job Id: 661 # of Openings: 1 Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE...

Position: Staff Software Engineer (Medical Imaging) Location: Doha, Qatar Job Id: 661 # of Openings: 1 Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE...

Position: Software Quality Test Engineer Location: Doha, Qatar Job Id: 660 # of Openings: 2 Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE study...

Position: Manager / Sr. Manager, Regulatory Affairs Location: Doha, Qatar Job Id: 666 # of Openings: 1 Akura Medical Overview Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval...